30 November 2023

Manager, Company Announcements ASX Limited Level 4 20 Bridge Street SYDNEY NSW 2000

Via E-Lodgement

Dear Sir/Madam

Mayne Pharma Group Limited

Please find attached the AGM presentation which contains a business update to be delivered to shareholders at Mayne Pharma's Annual General Meeting today at 10.00am (Melbourne time) at Minter Ellison, Level 20, Collins Arch, 447 Collins St, Melbourne VIC 3000.

The meeting will be webcast at https://meetnow.global/M2DMXJC.

This announcement is authorised by the Board.

Yours faithfully, Mayne Pharma Group Limited

LauraDhoph

Laura Loftus Company Secretary

For further information contact:

Australia: Craig Haskins +61 421 029 843 <u>ir@maynepharma.com</u> US: Lisa M. Wilson +1 917-543-9932 ir@maynepharma.com



Mayne Pharma Group Limited ABN 76 115 832 963 maynepharma.com T +61 8 8209 2666 F +61 8 8281 0284 1538 Main North Road, Salisbury South, SA 5106 Australia PO Box 700, Salisbury, SA 5108 Australia



Annual 10.00an

Mayne Pharma Group Limited

Annual General Meeting 10.00am (Melbourne time) 30 November 2023





Disclaimer

The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company's audited Financial Statements and market disclosures. This material is not intended to be relied upon as advice to investors or potential investors.

Forward looking statements

• This presentation contains forward-looking statements that involve subjective judgement and analysis and are subject to significant uncertainties, risks and contingencies, many of which are outside the control of, and are unknown to the Company. These forward looking statements use words such as 'potential', 'expect', 'anticipate', 'intend', 'plan' and 'may', and other words of similar meaning. No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by any person (including the Company). Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based. Given these uncertainties, readers are cautioned not to place undue reliance on such forward looking statements. Subject to the Company's continuous disclosure obligations at law and under the listing rules of the Australian Securities Exchange, the Company disclaims any obligation to update or revise any forward looking statements. The factors that may affect the Company's future performance include, among others: changes in economic conditions, changes in the legal and regulatory regimes in which the Company operates, litigation or government investigations, decisions by regulatory authorities, changes in behaviour of major customers, suppliers and competitors, interruptions to manufacturing or distribution, the success of research and development activities and research collaborations and the Company's ability to protect its intellectual property.

Other

- A glossary of industry terminology is contained in the Mayne Pharma Annual Report which can be accessed at <u>maynepharma.com/investor-relations/results-reports</u> and product descriptions are detailed at <u>maynepharma.com/us-products</u> and <u>maynepharma.com/au-products</u>.
- DORYX[®], FABIOR[®], LEXETTE[®], RHOFADE[®] and SORILUX[®] are trademarks of Mayne Pharma. ABSORICA[®], ACZONE[®], ANNOVERA[®], BIJUVA[®], EPIDUO[®] FORTE IMVEXXY[®], NEXTSTELLIS[®], ORACEA[®] and VITAMEDMD[®] are trademarks of third parties.



How to ask a question

- To ask a written question select the Q & A icon
- Select the topic your question relates to from the drop-down list
- Type your question in the text box and **press** the send button
- To ask a verbal question follow the instructions below the broadcast window

Broadcast	Vote	Q & A	Documents
Your question(s)			
You may enter a qu	estion using	the field below.	
Select Topic 🔻			
Questions are limited t	o 2000 charac	ters.	
		0 charact	Send



How to vote

- When the poll is open, select the vote icon at the top of the screen
- To vote, select either For, Against or Abstain
- You will see a vote confirmation
- To change or cancel your vote "click here to change your vote" at any time until the poll is closed

Broadcast	Vote	Q & A	Documents
Items of Busi	ems of Business		
2A Re-elect Mr Sam Sample as a Director			
FOR	AGAINST		ABSTAIN
2B Re-elect Ms Jane Citizen as a Director We have received your vote For Click here to change your vote.			

Introduction



Frank Condella **Chair**



Prof Bruce Robinson Non-Executive Director



David Petrie Non-Executive Director



Shawn Patrick O'Brien CEO & Managing Director



Dr Katie Macfarlane Non-Executive Director



Ann Custin Non-Executive Director



Patrick Blake Non-Executive Director



Aaron Gray **CFO**

mayne pharma



Agenda

1	Chair's Address
2	Business Update
3	Formal Business
4	Closing



Chair's Address

Frank Condella





Business Update

Shawn Patrick O'Brien





USe

personal

For

Agenda

- FY23 Performance and Financial Key Highlights
- YTD Oct-FY24 Unaudited Update
- Women's health segment
- Dermatology segment
- International segment
- Strategy, Outlook and Capital Management



<u>|uo</u>


USe

personal

Mayne Pharma at a Glance

Capitalising on commercial opportunities across three attractive business units

Putting the right people, products, and processes in place to address the needs of patients and drive long-term sustainable growth in each of our three segments



1. Based on size of US Women's Health Commercial Operations calling on OB/GYNs

2. IQVIA recent 12-month TRx totals by molecule, October 2023



FY23 Performance Highlights

REFOCUSED ON CORE BUSINESS

- Completed sale of Metrics Contract Services and US Retail Generics for a combined sale price of US\$565m
- Expanded US Women's Health portfolio via license of exclusive rights to commercialise a portfolio of on-market women's health products



IMPROVED FINANCIAL PERFORMANCE & RESET CAPITAL STRUCTURE

- Delivered revenue growth across all segments 2H vs. 1H FY23
- Positive 2H direct contribution and operating free cash flow
- Transformed balance sheet net cash of \$176.2m (vs FY22 net debt \$317m)
- Delivered \$46.7m special dividend and commenced on-market buyback up to 10% of the Company's issued capital



GREW ALL THREE SEGMENTS

- BPD/Women's Health strong revenue growth following relaunch of NEXTSTELLIS[®] and 2H launch of women's health portfolio products; significant 2H improvement in segment gross profit and direct contribution
- PPD/Dermatology delivered significant
 2H turnaround in revenue and gross profit as new commercial discipline introduced to rebase business following poor 1H result
- International revenue, gross profit and direct contribution growth delivered in 2H; commenced business improvement program to improve plant efficiency and secure international CDMO growth



USe

or personal

FY23 Financial Overview

- Results are presented from continuing operations to exclude Metrics Contract Services (MCS) which was divested on 4 October 2022 and to
 exclude the US Retail Generics business (previously included in the Portfolio Products (PPD) segment) which was divested on 7 April 2023. The
 results include adjustments to reflect movements to adjust FY22 results to a comparable basis.
- Group Revenue up 17% as growth in BPD (NEXTSTELLIS[®] and contribution from portfolio of women's health products licenced under the exclusive licencing agreement with TXMD 31 December 2022) and International business exceed decline in PPD (dermatology).
- Increase of reported Gross Profit is offset by a decline in margin in FY22 reflecting challenges in PPD (dermatology)
- Reported EBITDA loss reflects higher operating expenses to support future growth
- Reported Net Loss after tax includes \$215.4m expenses therein \$134.7m related to depreciation & amortisation and asset (primarily intangibles) impairments, \$47.7m income tax expense, \$28.8m finance expenses primarily discount unwind on earnouts.

A\$ million ¹	FY23	FY22	Change
Reported Revenue	\$183.6	\$157.1	\$26.5
Reported Gross Profit	\$83.5	\$71.6	\$11.9
Reported EBITDA	(\$102.0)	\$9.0	(\$111.0)
Reported Net Loss After Tax	(\$317.4)	(\$220.1)	(\$97.3)
Underlying EBITDA ²	(\$95.3)	(\$59.6)	(\$35.7)



YTD Oct-FY2024 Update¹

GROUP in A\$ m	Jul-Oct FY23	Mar-Jun FY23	Jul-Oct FY24
Total Net Sales	33.0	97.8	124.8
Total Gross Margin	13.5	47.8	71.7
Total Gross Margin % of Net Sales	41%	49%	57%
Direct OPEX	38.6	43.1	45.3
Indirect OPEX	22.6	23.1	25.7
Underlying EBITDA	-47.3	-17.9	1.0
Earn-out payment liability	-1.6	-1.1	-5.0
Lease payments	-1.1	-1.1	-1.3

Pivoting to growth

Strong total company results

- All 3 operating segments delivered positive contribution margin³ for Q1
- Net sales up 27.5% vs prior 4-month period
- Gross margin up 50.1% vs prior 4-month period
- Initiated a new targeted cost management program, removing US\$10M of costs
- Proposed increase to share buyback program

only S **Recurring payments** excluded from EBITDA² or persona

Dermatology gaining momentum

- Net sales of US\$35.9M, up 55.5% on prior 4-month
- Gross margin recovery reflecting core portfolio profitability and new product launches

Women's Health fundamentals improving

- Net sales of US\$30.6M, up 45.3% vs prior 4-month
- NEXTSTELLIS[®] net selling price (NSP) restored to prior levels
- Licensed TXMD products generating robust returns, maintaining conservative gross-to-net (GTN)

1. All YTD-Oct-FY24 results unaudited

- 2. Earn-out liability and lease payment amounts are balance sheet expenditures. The earn-out amount is based on actual sales
- 3. Contribution margin calculated as gross margin less direct OPEX excludes allocation of shared functions & overhead



BPD (Women's Health)






only

USe

Women's Health / Branded Products Division (BPD)

Leader in US Women's Health

- A leading position in strong and growing market with four novel women's healthcare products
- Licensing rights acquisition added a complementary portfolio of stable products with long patent lives to the Company's flagship women's health product, NEXTSTELLIS[®]
- One of the top 2 specialised women's health companies in the US¹
- Strong commercial infrastructure in place with sales team of 94 able to reach target customers





Women's Health / Branded Products Division (BPD)

YTD October FY24 results¹

- YTD-FY24 net sales +45.3% for BPD on prior 4-month period
- Segment performance reflects growth in expansion portfolio as well as improved performance of NEXTSTELLIS[®] following access improvements (co-pay) and new targeting strategy implemented in December 2022
- Continuing to refine NEXTSTELLIS[®] marketing strategy: reduction of DTC due to insufficient ROI and removed 6 non-profitable territories
- Direct OPEX increase vs prior year driven by sales force expansion; but have eliminated US\$8 million in segment costs for fiscal year 24
- YTD-FY24 gross margin representative of go-forward profile

BPD in US\$ m	Jul-Oct FY23	Mar-Jun FY23	Jul-Oct FY24
Total Net Sales	5.6	21.1	30.6
Total Gross Margin	4.5	18.8	25.2
Total Gross Margin % of Net Sales	81%	89%	82%
Direct OPEX	15.5	21.0	19.8
Direct Contribution	-11.0	-2.2	5.4
Earn-out payment liability	0.0	0.8	-2.7

FY24 Women's Health Outlook



- Complete integration of expansion portfolio with a focus on growth and improving net selling prices
- Deliver Rx growth across all brands
- Continued growth of NEXTSTELLIS[®]
- BIJUVA[®] low strength launch Q3 FY24
- ACA law enforcement
 impact

1. All YTD-FY24 results unaudited

2. Direct contribution calculated as gross margin less direct OPEX – excludes allocation of shared functions & overhead incl med affairs



Dermatology





or personal use only

Dermatology / Portfolio Products Division (PPD)

YTD October FY24 results¹

- YTD-FY24 Net Sales +640% vs PCP, +55.5% vs prior 4-month period
- YTD-FY24 Gross Margin +999+% vs PCP, +174% vs prior 4-month period
- Net revenues growing steadily, benefitting from improved GTN and NPLs (DORYX[®] MPC 60 mg, AG ORACEA[®])
- Unique prescriber patient fulfilment process (disintermediation) is active
- Co-pay monitoring expected to deliver improvements beginning Q2 and continuing throughout the FY

Derm in US\$ m	Jul-Oct FY23	Mar-Jun FY23	Jul-Oct FY24
Total Net Sales	4.9	23.1	35.9
Total Gross Margin	-0.2	5.7	15.6
Total Gross Margin % of Net Sales	-4%	25%	43%
Direct OPEX	7.3	5.4	7.1
Direct Contribution	-7.5	0.2	8.5
Earn-out payment liability	-1.0	0.0	-0.5



- Positive profit and contribution FY24
- Revenue growth via new/recent product launches (RHOFADE[®], isotretinoin, generic of ORACEA[®], DORYX[®] MPC 60 mg)
- Transition unique prescriber patient fulfilment process from pilot to fully scaled operation
- Enter into accretive business arrangements and drive commercial excellence

- All YTD-FY24 results unaudited 1.
- 2. Direct contribution calculated as gross margin less direct OPEX excludes allocation of shared functions & overhead incl med affairs



Dermatology / Portfolio Products Division (PPD)

Building market leadership and scale

- Five proprietary brands and 20 generic dermatologics
- Recent acquisition of RHOFADE[®], an FDA-approved topical cream used to treat rosacea (launched 10/2/2023)
- Mayne Pharma portfolio can fill 1 in 3 US Dermatology Retail Rx's¹
- Market presence as top 10 US products by revenue gABSORICA[®] (isotretinoin) capsules, gEPIDUO[®] FORTE (adapalene/benzoyl peroxide) gel and gACZONE[®] (dapsone) gel
- Building on market position with a strong and profitable pipeline of products to meet broader patient needs
- Differentiated channel strategy through specialty pharmacy growth and online platforms like GoodRx



only

USe



International





use only

personal

O

International

YTD October FY24 results¹

- YTD-FY24 net sales and margin down on prior 4-month period, driven primarily by timing
- Costs continue to be managed and our ongoing productivity initiatives are designed to deliver benchmark outcomes in pharma manufacturing
- The new business pipeline to drive large and long run volumes through our FDA and TGA registered Salisbury facility is building; focused on converting these into real opportunities
- Continued progress in growing Opioid
 Substitution Therapy (OST)
 opportunities in Europe



International in A\$ m	Jul-Oct FY23	Mar-Jun FY23	Jul-Oct FY24
Total Net Sales	17.5	31.2	21.3
Total Gross Margin	7.1	10.3	8.0
Total Gross Margin % of Net Sales	40%	33%	37%
Direct OPEX	4.0	3.9	3.9
Direct Contribution	3.1	6.4	4.0
Earn-out payment liability	-0.1	-0.1	-0.1

FY24 International Outlook

- Pursue targeted investments and new manufacturing revenue streams
- Continue to drive specialty and generic product sales including NEXTSTELLIS[®] in Australia
- Invest in a targeted manner in the Salisbury facility to improve our productivity and capabilities

1. All YTD-FY24 results unaudited

2. Direct contribution calculated as gross margin less direct OPEX – excludes allocation of shared functions & overhead incl med affairs



Strategy, Outlook and Capital Management



Strategy for 2024 Growth

Continuing positive momentum into FY24 – solid Q1 momentum continuing into Q2

only USe **1**FY24

Deliver positive contribution margins in all three segments

CReturn Company to positive EBITDA and cash generation in FY24

Optimise cost base with OPEX & Other reductions of > US\$10M



- Complete integration of licensed portfolio with a focus on growth and improving net selling prices
- Deliver Rx growth across all branded products
- NEXTSTELLIS[®] breakeven run rate in 1HFY24¹
- BIJUVA[®] low strength launch Q3
- ACA law enforcement impact

Dermatology

- Positive profit and contribution FY24
- New product launches
- Transition unique prescriber patient fulfilment process from pilot to fully scaled operation
- Enter into accretive business arrangements and drive commercial excellence

International



- Pursue targeted investments and new manufacturing revenue streams
- Continue to drive specialty and generic product sales including NEXTSTELLIS[®] in Australia
- Invest in a targeted manner in the Salisbury facility to improve our productivity and capabilities



Capital Management

Jul-Oct FY 2024

Current company cash balance A\$163.9m Oct 31, 2023

Cash uses first 4 months FY24 (A\$) 61.5m

D	Cash used: Financing & investing	25.5m
A	RHOFADE® transaction	<u>13.1m</u>
	Share repurchase RHOFADE [®] transaction	1.4m
	Repayment receivable facility	10.7m
\mathbf{U}_{1}		

Cash used: Operations

36.0m

Operations includes ~A\$30m+ outflows related to discontinued operations.

FY24 Capital Management Priorities

- Maintain conservative balance sheet and solid liquidity position through transition phase with planned capital structure review ongoing
- Execute on invested portfolio, no acquisitions planned
- Improvement in cash conversion cycle (Inventory + AR Q1FY24 reduced A\$92M vs pcp)
- Tight management of discontinued business obligations / provisions
- Improve leverage on fixed assets (PP&E efficiency and utilisation Salisbury)
- Accelerate share buy-back:
 - Current 10% limit (2.7m shares bought back, A\$10.5m at 29 Nov)
 - AGM proposal to increase the buy-back capacity to up to 15% in the next 12 months

Further improvement in profitability & management of discontinued operations expected to deliver positive operating cash Q2 through Q4



Formal Business

Frank Condella





General business – item 1

• To receive and consider the Director's Report, Financial Statements and the Independent Auditors Report for the financial year ended 30 June 2023



Resolution 1

Re-election of Mr Frank Condella





General business – Resolution 1

Proxy results: Re-Election of Mr Frank Condella			
43,168,545 shares	98.33%	Shares to be voted in favour	
432,465 shares	0.99%	Shares to be voted against	
54,419 shares	N/A	Shares to abstain from voting	
297,539 shares	0.68%	Shares open to proxy holders	



Resolutions 2 and 3

Re-election of Mr Patrick Blake Election of Ms Anne Lockwood





General business – Resolution 2

Proxy results: Re-Election of Mr Patrick Blake			
43,166,063 shares	98.34%	Shares to be voted in favour	
433,201 shares	0.98%	Shares to be voted against	
57,919 shares	N/A	Shares to abstain from voting	
295,785 shares	0.68%	Shares open to proxy holders	



General business – Resolution 3

Proxy results: Election of Ms Anne Lockwood			
43,051,073 shares	98.20%	Shares to be voted in favour	
493,338 shares	1.12%	Shares to be voted against	
114,272 shares	N/A	Shares to abstain from voting	
295,785 shares	0.68%	Shares open to proxy holders	



Resolution 4

Adoption of Remuneration Report





Changes to remuneration

- Short term incentive introduced in FY23 to better align with market practice
- KPIs set for FY24 for CEO and CFO:
 - EBITDA target (25% weighting)
 - Operating cash flow target (25% weighting)
 - Achievement of target NEXTSTELLIS[®] business results (20% weighting)
 - Achievement of targeted gross contribution margin for ANNOVERA[®], BIJUVA[®], IMVEXXY[®], NEXTSTELLIS[®] and pre-natal vitamins (15% weighting)
 - Cost management / cost structure targets as defined by the board of directors (15% weighting)
- 50% of any STI awarded deferred into equity

LTI percentage reduced as part of the package of changes with the introduction of STI

- Single test point at three years (re-testing removed)
- For LTI to vest, annual TSR of between 8% and 15% must be achieved (this equates to return of between 26% and 52% over the total period)
- For example, for CEO grant, if base test price is \$5.00, then for LTI to vest, the 30-day VWAP for Mayne Pharma shares must be between \$6.30 (for 20% vesting) and \$7.60 (for 100% vesting) at the testing date

Short Term Incentive

USG

oersonal

Long Term Incentive



General business – Resolution 4

Proxy results: Adoption of Remuneration Report				
28,062,065 shares	65.23%	Shares to be voted in favour		
14,658,927 shares	34.08%	Shares to be voted against		
152,430 shares	N/A	Shares to abstain from voting		
293,916 shares	0.69%	Shares open to proxy holders		



Resolution 5

Issue of Short-Term Incentive grant of Restricted Stock Unit Performance Rights and Long-Term Incentive grant of Performance Rights under the Employee Performance Rights and Option Plan (PROP) to the CEO and Managing Director



General business – Resolution 5

Proxy results: Issue of Short-Term Incentive grant of Restricted Stock Unit Performance Rights and Long-Term Incentive grant of Performance Rights under the Employee Performance Rights and Option Plan (PROP) to the CEO and MD				
29,652,463 shares	67.76%	Shares to be voted in favour		
13,820,372 shares	31.58%	Shares to be voted against		
194,943 shares	N/A	Shares to abstain from voting		
286,690 shares	0.66%	Shares open to proxy holders		



Resolution 6

Appointment of BDO Audit Pty Ltd as Auditor





General business – Resolution 6

Proxy results: Appointment of BDO Audit Pty Ltd as Auditor				
43,306,492 shares	98.82%	Shares to be voted in favour		
218,539 shares	0.50%	Shares to be voted against		
132,202 shares	N/A	Shares to abstain from voting		
297,235 shares	0.68%	Shares open to proxy holders		



Resolution 7

Extension of On-Market Share Buy Back





General business – Resolution 7

Proxy results: Extension of On-Market Share Buy Back				
43,447,374 shares	99.00%	Shares to be voted in favour		
140,780 shares	0.32%	Shares to be voted against		
70,679 shares	N/A	Shares to abstain from voting		
295,635 shares	0.68%	Shares open to proxy holders		



Annual 10.00an

Mayne Pharma Group Limited

Annual General Meeting 10.00am (Melbourne time) 30 November 2023

